Cargando…

Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs

Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spector, Daniil, Pavlov, Kirill, Beloglazkina, Elena, Krasnovskaya, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739791/
https://www.ncbi.nlm.nih.gov/pubmed/36498837
http://dx.doi.org/10.3390/ijms232314511
_version_ 1784847896031526912
author Spector, Daniil
Pavlov, Kirill
Beloglazkina, Elena
Krasnovskaya, Olga
author_facet Spector, Daniil
Pavlov, Kirill
Beloglazkina, Elena
Krasnovskaya, Olga
author_sort Spector, Daniil
collection PubMed
description Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review.
format Online
Article
Text
id pubmed-9739791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97397912022-12-11 Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs Spector, Daniil Pavlov, Kirill Beloglazkina, Elena Krasnovskaya, Olga Int J Mol Sci Review Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review. MDPI 2022-11-22 /pmc/articles/PMC9739791/ /pubmed/36498837 http://dx.doi.org/10.3390/ijms232314511 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spector, Daniil
Pavlov, Kirill
Beloglazkina, Elena
Krasnovskaya, Olga
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title_full Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title_fullStr Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title_full_unstemmed Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title_short Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
title_sort recent advances in light-controlled activation of pt(iv) prodrugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739791/
https://www.ncbi.nlm.nih.gov/pubmed/36498837
http://dx.doi.org/10.3390/ijms232314511
work_keys_str_mv AT spectordaniil recentadvancesinlightcontrolledactivationofptivprodrugs
AT pavlovkirill recentadvancesinlightcontrolledactivationofptivprodrugs
AT beloglazkinaelena recentadvancesinlightcontrolledactivationofptivprodrugs
AT krasnovskayaolga recentadvancesinlightcontrolledactivationofptivprodrugs